HPV Vaccines: Preclinical Development

Galloway, 1992, Serological assays for the detection of HPV antibodies, 147 Jochmus-Kudielka, 1989, Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer, J Natl Cancer Inst, 81, 1698, 10.1093/jnci/81.22.1698 Meschede, 1998, Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer, J Clin Microbiol, 36, 475, 10.1128/JCM.36.2.475-480.1998 Hagensee, 2000, Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions, J Infect Dis, 181, 1234, 10.1086/315364 Onda, 2003, Characterization of IgA response among women with incident HPV 16 infection, Virology, 312, 213, 10.1016/S0042-6822(03)00196-X Ho, 2002, Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles, J Infect Dis, 186, 737, 10.1086/342972 Viscidi, 2003, Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women, J Infect Dis, 187, 194, 10.1086/346052 Pastrana, 2005, Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2, Virology, 337, 365, 10.1016/j.virol.2005.04.011 Breitburd, 1995, Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection, J Virol, 69, 3959, 10.1128/JVI.69.6.3959-3963.1995 Kirnbauer, 1996, Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization, Virology, 219, 37, 10.1006/viro.1996.0220 Suzich, 1995, Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas, Proc Natl Acad Sci USA, 92, 11553, 10.1073/pnas.92.25.11553 Pilacinski, 1986, Immunization against bovine papillomavirus infection, Ciba Found Symp, 120, 136 Ghim, 2000, Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus, Exp Mol Pathol, 68, 147, 10.1006/exmp.1999.2298 Thones, 2008, A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response, J Virol, 82, 5472, 10.1128/JVI.02482-07 Stahl-Hennig, 2009, Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques, PLoS Pathog, 5, 10.1371/journal.ppat.1000373 Makowski, 1980, Structural studies of the assembly of simple viruses, Prog Clin Biol Res, 40, 233 Salunke, 1986, Self-assembly of purified polyomavirus capsid protein VP1, Cell, 46, 895, 10.1016/0092-8674(86)90071-1 Kirnbauer, 1993, Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles, J Virol, 67, 6929, 10.1128/JVI.67.12.6929-6936.1993 Combita, 2002, Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer, Int J Cancer, 97, 796, 10.1002/ijc.10153 Pastrana, 2004, Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18, Virology, 321, 205, 10.1016/j.virol.2003.12.027 Brown, 2004, Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine, Vaccine, 22, 2936, 10.1016/j.vaccine.2003.11.059 Harro, 2001, Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine, J Natl Cancer Inst, 93, 284, 10.1093/jnci/93.4.284 Carter, 2000, Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection, J Infect Dis, 181, 1911, 10.1086/315498 Fausch, 2003, Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells, Cancer Res, 63, 3478 Koromilas, 2001, Control of interferon signaling in human papillomavirus infection, Cytokine Growth Factor Rev, 12, 157, 10.1016/S1359-6101(00)00023-X Nardelli-Haefliger, 2003, Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles, J Natl Cancer Inst, 95, 1128, 10.1093/jnci/djg018 Balmelli, 1998, Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions, J Virol, 72, 8220, 10.1128/JVI.72.10.8220-8229.1998 Ruiz, 2005, Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant, J Immune Based Ther Vaccines, 3, 2, 10.1186/1476-8518-3-2 De Gregorio, 2008, Alum adjuvanticity: unraveling a century old mystery, Eur J Immunol, 38, 2068, 10.1002/eji.200838648 Baldridge, 2004, Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents, Expert Opin Biol Ther, 4, 1129, 10.1517/14712598.4.7.1129 Ismaili, 2002, Monophosphoryl lipid A activates both human dendritic cells and T cells, J Immunol, 168, 926, 10.4049/jimmunol.168.2.926 Rambout, 2007, Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials, CMAJ, 177, 469, 10.1503/cmaj.070948 Opalka, 2003, Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay, Clin Diagn Lab Immunol, 10, 108, 10.1128/CDLI.10.1.108-115.2003 Einstein MH. On behalf of the HPV-010 Study group. Immune response after primary vaccination course: a comparative trial of two prophylactic vaccines. In: Dillner J, ed. 25th International Papillomavirus Conference. Malmö/Sweden; 2009. Harper, 2004, Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, Lancet, 364, 1757, 10.1016/S0140-6736(04)17398-4 Villa, 2006, Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18, Vaccine, 24, 5571, 10.1016/j.vaccine.2006.04.068 Giuliano, 2007, Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine, J Infect Dis, 196, 1153, 10.1086/521679 Harper, 2006, Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial, Lancet, 367, 1247, 10.1016/S0140-6736(06)68439-0 Olsson, 2007, Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine, Vaccine, 25, 4931, 10.1016/j.vaccine.2007.03.049 Lehtinen, 2006, Enrollment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing, Int J STD AIDS, 17, 517, 10.1258/095646206778145550 Wheeler, 2009, The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years, J Infect Dis, 199, 936, 10.1086/597309 Alphs, 2008, Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2, Proc Natl Acad Sci USA, 105, 5850, 10.1073/pnas.0800868105 Pastrana, 2005, Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2, Virology, 337, 365, 10.1016/j.virol.2005.04.011 DeFilippis, 2003, Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells, J Virol, 77, 1551, 10.1128/JVI.77.2.1551-1563.2003 Butz, 2003, siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells, Oncogene, 22, 5938, 10.1038/sj.onc.1206894 Chen, 2000, Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16, Mol Cell, 5, 557, 10.1016/S1097-2765(00)80449-9 Schädlich, 2009, Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity, J Virol, 83, 10.1128/JVI.02588-08 Biemelt, 2003, Production of human papillomavirus type 16 virus-like particles in transgenic plants, J Virol, 77, 9211, 10.1128/JVI.77.17.9211-9220.2003 Maclean, 2007, Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization, J Gen Virol, 88, 1460, 10.1099/vir.0.82718-0 Nardelli-Haefliger, 2005, Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine, Vaccine, 23, 3634, 10.1016/j.vaccine.2005.02.019 Schiller, 2006, Chapter 17: Second generation HPV vaccines to prevent cervical cancer, Vaccine, 24, S147, 10.1016/j.vaccine.2006.05.123 Kuck, 2006, Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1, J Virol, 80, 2621, 10.1128/JVI.80.6.2621-2630.2006 Revaz, 2007, Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants, Antiviral Res, 76, 75, 10.1016/j.antiviral.2007.05.005